• 1
    Timpl R,Sasaki T,Kostka G,Chu ML. Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 2003; 4: 47989.
  • 2
    Forti S,Scanlan MJ,Invernizzi A,Castiglioni F,Pupa S,Agresti R,Fontanelli R,Morelli D,Old LJ,Pupa SM,Ménard S. Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum. Breast Cancer Res Treat 2002; 73: 24556.
  • 3
    Greene LM,Twal WO,Duffy MJ,McDermott EW,Hill AD,O'Higgins NJ,McCann AH,Dervan PA,Argraves WS,Gallagher WM. Elevated expression and altered processing of fibulin-1 protein in human breast cancer. Br J Cancer 2003; 88: 8718.
  • 4
    Roger P,Pujol P,Lucas A,Baldet P,Rochefort H. Increased immunostaining of fibulin-1, an estrogen-regulated protein in the stroma of human ovarian epithelial tumors. Am J Pathol 1998; 153: 157988.
  • 5
    Clinton GM,Rougeot C,Derancourt J,Roger P,Defrenne A,Godyna S,Argraves WS,Rochefort H. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells. Proc Natl Acad Sci USA 1996; 93: 31620.
  • 6
    Gallagher WM,Greene LM,Ryan MP,Sierra V,Berger A,Laurent-Puig P,Conseiller E. Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumor tissues. FEBS Lett 2001; 489: 5966.
  • 7
    Schiemann WP,Blobe GC,Kalume DE,Pandey A,Lodish HF. Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-beta and affects protein kinase cascades. J Biol Chem 2002; 277: 2736777.
  • 8
    Yi CH,Smith DJ,West WW,Hollingsworth MA. Loss of fibulin-2 expression is associated with breast cancer progression. Am J Pathol 2007; 170: 153545.
  • 9
    Argraves WS,Greene LM,Cooley MA,Gallagher WM. Fibulins: physiological and disease perspectives. EMBO Rep 2003; 4: 112731.
  • 10
    Gallagher WM,Currid CA,Whelan LC. Fibulins and cancer: friend or foe? Trends Mol Med 2005; 11: 33640.
  • 11
    Klenotic PA,Munier FL,Marmorstein LY,Anand-Apte B. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem 2004; 279: 3046973.
  • 12
    Albig AR,Neil JR,Schiemann WP. Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006; 66: 26219.
  • 13
    Banerjee S,Dowsett M,Ashworth A,Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 2007; 4: 53650.
  • 14
    Rhiem K,Klein A,Munch M,Kreutzfeld R,Ramser J,Wardelmann E,Schackert G,Von Deimling A,Wiestler OD,Schmutzler RK. Chromosomal region 15q21.1 is a frequent target of allelic imbalance in advanced breast carcinomas. Int J Cancer 2003; 106: 747.
  • 15
    Niederacher D,Picard F,van Roeyen C,An HX,Bender HG,Beckmann MW. Patterns of allelic loss on chromosome 17 in sporadic breast carcinomas detected by fluorescent-labeled microsatellite analysis. Genes Chromosomes Cancer 1997; 18: 18192.
  • 16
    Veeck J,Niederacher D,An H,Klopocki E,Wiesman F,Betz B,Galm O,Camara O,Dürst M,Kristiansen G,Huszka C,Knüchel R, et al. Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavorable prognosis. Oncogene 2006; 25: 347988.
  • 17
    Fink L,Seeger W,Ermert L,Haenze J,Stahl U,Grimminger F,Kummer W,Bohle RM. Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 1998; 4: 132933.
  • 18
    Kobayashi N,Kostka G,Garbe JHO,Keene DR,Bächinger HP,Hanisch FG,Markova D,Tsuda T,Timpl R,Chu ML,Sasaki T. A comparative analysis of the fibulin protein family: biochemical characterization, binding interactions and tissue localization. J Biol Chem 2007; 282: 1180516.
  • 19
    Giltay R,Timpl R,Kostka G. Sequence, recombinant expression and tissue localization of two novel extracellular matrix proteins, fibulin-3 and fibulin-4. Matrix Biol 1999; 18: 46980.
  • 20
    Harbeck N,Alt U,Krüger A,Berger U,Thomssen C,Jänicke F,Höfler H,Kates RE,Schmitt M. Prognostic impact of proteolytic factors (uPA. PAI-1, cathepsins. B, D, L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res 2001; 7: 275764.
  • 21
    Dahl E,Sadr-Nabavi A,Klopocki E,Betz B,Grube S,Kreutzfeld R,Himmelfarb M,An HX,Gelling S,Klaman I,Hinzmann B,Kristiansen G, et al. Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer. J Pathol 2005; 205: 218.
  • 22
    Yue W,Dacic S,Sun Q,Landreneau R,Guo M,Zhou W,Siegfried JM,Yu J,Zhang L. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 2007; 13: 433644.
  • 23
    Wang D,Anderson JC,Gladson CL. The role of the extracellular matrix in angiogenesis in malignant glioma tumors. Brain Pathol 2005; 15: 31826.
  • 24
    Viens P,Jacquemier J,Bardou VJ,Bertucci F,Penault-Llorca F,Puig B,Gravis G,Oziel-Taïeb S,Resbeut M,Houvenaeghel G,Camerlo J,Birbaum D, et al. Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy. Breast Cancer Res Treat 1999; 54: 20512.
  • 25
    Lennernäs B,Albertsson P,Lennernäs H,Norrby K. Chemotherapy and antiangiogenesis. Acta Oncol 2003; 42: 294303.